AlphAIalphai — Financial news for AI agents
rttnews.comJUL 64 min read$SBEV

Splash Beverage Group Secures Exclusive Global Rights To CannEpil For Drug- Resistant Epilepsy

Splash Beverage Group (SBEV) said it secured exclusive global licensing rights to CannEpil, a pharmaceutical-grade cannabinoid therapy for drug-resistant epilepsy, from Argent BioPharma (RGT.AX). CannEpil has patient access in Ireland, UK, Germany and Australia under EU-GMP, with Ireland MCAP reimbursement support and UK Named Patient Request import/prescription. SBEV cited pre-IND/IND progress for U.S. development.

Original reporting
rttnews.com
Published Jul 6, 2026, 6:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 6:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Splash Beverage Group Secures Exclusive Global Rights To CannEpil For Drug- Resistant Epilepsy — source image
Source · rttnews.com
Decision brief

The 30-second read

$SBEVBullishMed
01

Why it matters

The exclusive global licensing agreement is the primary new catalyst, with additional context that the program has engaged the U.S. FDA via pre-IND and has an IND number, supporting a potential U.S. development path.

02

Market read

Traders may reassess SBEV’s therapeutics pipeline value based on a new exclusive licensing asset and stated U.S. regulatory engagement.

03

What to watch

Key missing details include upfront payment, milestone structure, who funds U.S. trials, exclusivity scope (territory/indications), and whether CannEpil’s international access translates into U.S. efficacy/safety expectations.

Relevance 7/10Novelty 6/10Timing: today’s headline deal announcement; traders may reprice licensing/clinical optionality immediately

Background

CannEpil is described as a pharmaceutical-grade cannabinoid therapy for drug-resistant epilepsy with international patient access and EU-GMP manufacturing.

Company-level read

Ticker impact

$SBEVBullishMedium confidence
Context

Splash Beverage Group secured an exclusive global licensing agreement for CannEpil, expanding its cannabinoid therapeutics platform and pursuing U.S. development.

Expected impact

Near-term sentiment likely positive but magnitude uncertain without deal economics (upfront/milestones) or clinical/regulatory milestones.

Evidence & confidence

The article discloses a new exclusive global licensing agreement and mentions pre-IND/IND number and international access, but provides no financial terms or timeline for U.S. trials.

Market effects

Sector

Reinforces the trend of monetizing cannabinoid therapeutics via licensing and leveraging existing international access to accelerate U.S. regulatory pathways.

Regional

Highlights Europe-based access/reimbursement frameworks (Ireland/UK/Germany) as a template for U.S. pre-IND-to-IND development narratives.

Global

Signals cross-border commercialization activity in drug-resistant epilepsy therapies and cannabinoid-derived medicines.

Counterpoint

What could challenge this read

Without deal economics and a clear U.S. clinical timeline, the market may overestimate near-term value and underweight execution/regulatory risk.

Key entities

  • company
    Splash Beverage Group, Inc.

    Announced exclusive global licensing rights to CannEpil and positions it as a step to expand its cannabinoid therapeutics platform.

  • company
    Argent BioPharma Limited

    Licensor of CannEpil, granting exclusive global rights to Splash Beverage Group.

  • product
    CannEpil

    Cannabinoid therapy for drug-resistant epilepsy with described international access and U.S. pre-IND/IND progress.

Read at source← All news

Related articles

JUL 31
$SBEVMed

Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours Splash Bev

Splash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.

benzinga.com5 min
JUL 29
$SBEVMed

Splash Beverage Group Expands CannEpil Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Splash Beverage Group (NYSE American: SBEV) said it expanded its exclusive global CannEpil license to cover veterinary therapeutics. The company plans initial evaluation for companion-animal oncology and chronic pain, pursuing FDA Center for Veterinary Medicine INAD and Conditional Approval pathways. Splash will pay Argent BioPharma a 10% royalty on veterinary net revenues.

finanznachrichten.de4 min
JUL 14
$SBEVMedAI 8/10

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said it settled legacy creditor claims totaling about $3.3 million for about $550,000 cash, expecting an approximate $2.75 million gain from debt extinguishment, subject to final accounting. Its board approved a 1-for-4 reverse stock split to support NYSE American minimum price compliance, reducing shares from ~25.2M to ~6.3M, effective July 27, 2026.

manilatimes.net4 min
JUL 9
$SBEVMed

Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said NYSE American accepted its plan to regain continued listing compliance and granted a compliance period through Jan. 29, 2027, after the company submitted the plan on May 29, 2026. The company said it will execute strategic initiatives while maintaining its listing.

manilatimes.net3 min
JUL 7
$SBEVMedAI 8/10

SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL

Splash Beverage Group (NYSE American: SBEV) said it signed an exclusive global licensing deal with Argent BioPharma (ASX/LSE: RGT) for CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. CannEpil is approved for distribution in multiple countries and has initiated U.S. pre-IND/IND steps. Splash received a $1M investment commitment and will issue $5.5M preferred equity; Argent debt (~$5M) is forgiven. Argent earns a 15% net-revenue royalty.

prnewswire.com3 min
JUL 6
$SBEVMed

Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential

Splash Beverage Group (NYSE American: SBEV) said it acquired exclusive worldwide licensing rights to Argent BioPharma’s CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. The deal includes a $1M investment commitment from C/M Capital Partners and forgiveness of ~$5M debt by Mercer Street Global Opportunity Fund, plus $5.5M in SBEV preferred equity. Splash will pay a 15% royalty on net worldwide sales.

manilatimes.net3 min